Compare CubeSmart (CUBE) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Enveric Biosciences Inc — how do they compare? CubeSmart trades at $37.56 (market cap $8.45B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: CubeSmart is far larger — about 1242.6× Enveric Biosciences Inc's market cap, and CubeSmart pays a 5.65% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Enveric Biosciences Inc for 14 Days on average.
| CUBE | ENVB | |
|---|---|---|
Market Cap | $8.45B | $6.80M |
Volume | 2,879,532 | 64,867 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $10.80 |
52-Week Low | $35.36 | $1.27 |
Typical Hold Time | 89 Days | 14 Days |
Enterprise Value | $11.97B | -$1.49M |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.23, down 1.4% on the day, amid a bearish technical signal from moving averages. The self-storage REIT reported mixed Q2 2026 results with an FFO miss but revenue beat, and same-store NOI declined 0.7%. Financials show strong gross margins of 67.83% and net income margin of 29.41%, though net income has trended down from $411M in 2023 to $334M in 2025. Analyst consensus is a Buy with a $44.00 price target, implying 18% upside, but technical indicators suggest near-term resistance at $38.
CUBE offers a 5.4% dividend yield with a payout scheduled for October 2026, supporting income-focused investors. Upside is driven by moderating supply and strengthening demand in the self-storage sector, but risks include high leverage with $2.99B long-term debt and macroeconomic sensitivity. Institutional activity is mixed, with new positions from Deutsche Bank and Barrow Hanley offset by selling from HSBC. The stock presents a value opportunity if operational improvements materialize, though debt levels and same-store performance warrant caution.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
